X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (61) 61
oncology (61) 61
index medicus (48) 48
female (32) 32
aged (30) 30
male (30) 30
chemotherapy (28) 28
middle aged (25) 25
lung neoplasms - drug therapy (22) 22
carcinoma, non-small-cell lung - drug therapy (21) 21
adult (19) 19
cancer (19) 19
immunotherapy (19) 19
lung neoplasms - pathology (19) 19
carcinoma, non-small-cell lung - pathology (18) 18
care and treatment (18) 18
lung cancer (17) 17
neoplasm staging (16) 16
antibodies, monoclonal - therapeutic use (15) 15
lung cancer, non-small cell (15) 15
aged, 80 and over (14) 14
antineoplastic agents - therapeutic use (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
docetaxel (13) 13
analysis (12) 12
metastasis (12) 12
nivolumab (12) 12
treatment outcome (12) 12
trial (12) 12
open-label (11) 11
article (10) 10
lung neoplasms - therapy (10) 10
respiratory system (10) 10
antibodies, monoclonal - adverse effects (9) 9
carcinoma (9) 9
phase-iii trial (9) 9
bevacizumab (8) 8
cancer therapies (8) 8
cisplatin (8) 8
hematology, oncology and palliative medicine (8) 8
ipilimumab (8) 8
non-small cell lung carcinoma (8) 8
prognosis (8) 8
research (8) 8
survival (8) 8
therapy (8) 8
abridged index medicus (7) 7
antineoplastic agents (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
carcinoma, non-small-cell lung - therapy (7) 7
disease-free survival (7) 7
drug therapy (7) 7
mutation (7) 7
patients (7) 7
pembrolizumab (7) 7
safety (7) 7
survival rate (7) 7
1st-line treatment (6) 6
antibodies, monoclonal - administration & dosage (6) 6
cohort studies (6) 6
lung neoplasms - diagnosis (6) 6
multicenter (6) 6
solid tumors (6) 6
carboplatin (5) 5
carcinoma, non-small-cell lung - diagnosis (5) 5
chemistry (5) 5
erlotinib (5) 5
gemcitabine (5) 5
human necessities (5) 5
hygiene (5) 5
leukemia (5) 5
lung neoplasms - genetics (5) 5
medical or veterinary science (5) 5
metallurgy (5) 5
neoplasms - drug therapy (5) 5
non-hodgkins-lymphoma (5) 5
non-small cell lung cancer (5) 5
organic chemistry (5) 5
ovarian cancer (5) 5
peptides (5) 5
preparations for medical, dental, or toilet purposes (5) 5
1st-line therapy (4) 4
adenocarcinoma (4) 4
animals (4) 4
anti-cd20 monoclonal-antibody (4) 4
antimitotic agents (4) 4
apoptosis (4) 4
biomarkers (4) 4
blockade (4) 4
carboplatin - administration & dosage (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
cell lung-cancer (4) 4
clinical trials (4) 4
combination (4) 4
dosage and administration (4) 4
dose-response relationship, drug (4) 4
flow cytometry (4) 4
follow-up studies (4) 4
genetic aspects (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1497 - 1508
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 02/2016, Volume 374, Issue 5, pp. 493 - 494
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 17, pp. 1627 - 1639
Journal Article
Cancer, ISSN 0008-543X, 11/2019
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 25, pp. 2415 - 2426
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 02/2018, Volume 10, Issue Suppl 3, pp. S395 - S396
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 23, pp. 3701 - 3708
Purpose Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab... 
MULTIPLE-MYELOMA | RECEPTOR | THERAPY | ONCOLOGY | INTERLEUKIN-6 | CANCER | Young Adult | Castleman Disease - drug therapy | Humans | Middle Aged | Interleukin-6 - immunology | Adult | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Index Medicus
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 07/2019, Volume 15, Issue 19, pp. 2287 - 2302
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single... 
1ST-LINE TREATMENT | CTLA-4 BLOCKADE | nivolumab | SOLID TUMORS | MAINTENANCE BEVACIZUMAB | PHASE-III | atezolizumab | OPEN-LABEL | DOCETAXEL | STAGE IV | pembrolizumab | ANTI-PD-1 ANTIBODY | ONCOLOGY | tumor mutational burden | immunotherapy | ipilimumab | PD-L1 | CTLA-4 | PD-1 | non-small-cell lung cancer
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 09/2018, Volume 14, Issue 9, pp. 529 - 535
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 05/2018, Volume 16, Issue 5, pp. 364 - 374
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor... 
Programmed death ligand 1 (PD-L1) | Immune-related adverse events (irAEs) | Programmed death 1 (PD-1) | Immunotherapy
Journal Article